Berlex Laboratories applies to market Mirena in US:
This article was originally published in Clinica
Schering AG's Berlex Laboratories unit has filed a new drug application with the US FDA for its levonorgestrel-containing intra-uterine device, Mirena. The contraceptive, which delivers a small dose of locally acting hormone directly to the uterus, is marketed by Schering in countries in the European Union, Asia and Latin America, and is used by around 1.4 million women. It can remain in the uterus for five years, but can be removed at any time, and full fertility is restored within one month of removal, the company said.
You may also be interested in...
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.
Belgian developer of cancer diagnostics is building an infectious disease portfolio on the back of its new SARS-CoV-2 test and collaborations with Immunexpress and Endpoint Health.
If the tools are not in place by the end of 2020 to allow diagnostics companies to comply with the EU IVDR, the 2022 compliance deadline should be delayed, say EU notified bodies.